FOXM1 and plasma cell myeloma: Targeting the interactions and pathways described above – perhaps in conjunction with targeting FOXM1 directly using established [43] or emerging [44] small-drug inhibitors – may afford the re-sensitization of relapsed FOXM1High myeloma to Bz and other drugs that were effective at earlier stages of myeloma therapy.